List view / Grid view
24 March 2014 | By Merck
Merck announced that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver...
24 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim has announced that new findings from ongoing Pradaxa® research will be presented during the American College of Cardiology's 63rd Annual Scientific Session...
24 March 2014 | By AstraZeneca
AstraZeneca announced that the Japanese Ministry of Health, Labour and Welfare approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets)...
24 March 2014 | By The European Medicines Agency
Restrictions intended to limit risks of severe diarrhoea and effects on the liver...
24 March 2014 | By The European Medicines Agency
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the granting of a marketing authorisation for Sylvant (siltuximab)...
24 March 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives...
24 March 2014 | By The European Medicines Agency
Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond...
24 March 2014 | By The European Medicines Agency
This page provides an overview of the opinions adopted at the March 2014 meeting of the Committee for Medicinal Products for Human Use and other important outcomes...
21 March 2014 | By Novartis
Novartis announced that the Joint Committee on Vaccination and Immunisation in the UK has recommended the inclusion of Bexsero® (Meningococcal Group B Vaccine...
21 March 2014 | By Boehringer Ingelheim
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...
21 March 2014 | By Biogen Idec
The approval of ALPROLIX is first significant advance in hemophilia B treatment in more than 17 years ...
21 March 2014 | By The European Medicines Agency
Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies...
21 March 2014 | By METTLER TOLEDO
Take the worry out of weighing with new balances designed to aid compliance and process security...
20 March 2014 | By AbbVie
AbbVie announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab)...
20 March 2014 | By Johnson & Johnson
Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy...
